NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CSCI

COSCIENS Biopharma Inc

Apr 22 • 04:00PM ET

3.04

Dollar change -0.01
Percentage change -0.49	%

Healthcare • Biotechnology • Canada • NASD

Peers: AMGN GILD REGN VRTX BIIB BMY MRNA LLY INCY NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-23.59	Insider Own	1.48%	Shs Outstand	3.14M	Perf Week	4.30%
Market Cap	9.56M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.10M	Perf Month	-5.16%
Income	-19.66M	PEG	-	EPS next Q	-	Inst Own	8.85%	Short Float	0.67%	Perf Quarter	3.23%
Sales	7.53M	P/S	1.27	EPS this Y	-	Inst Trans	0.04%	Short Ratio	0.86	Perf Half Y	-18.19%
Book/sh	4.19	P/B	0.72	EPS next Y	-	ROA	-54.55%	Short Interest	0.02M	Perf Year	-61.58%
Cash/sh	5.20	P/C	0.58	EPS next 5Y	-	ROE	-125.39%	52W Range	1.96 - 11.10	Perf YTD	9.57%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.70%	ROI	-129.34%	52W High	-72.66%	Beta	0.80
Dividend TTM	-	Quick Ratio	2.95	Sales past 5Y	139.72%	Gross Margin	48.34%	52W Low	54.85%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	3.32	EPS Y/Y TTM	-73.03%	Oper. Margin	-243.02%	RSI (14)	54.30	Volatility	7.78% 9.78%
Employees	40	Debt/Eq	0.18	Sales Y/Y TTM	67.50%	Profit Margin	-260.95%	Recom	1.00	Target Price	60.00
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	53.74%	Payout	-	Rel Volume	0.15	Prev Close	3.05
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	2645.45%	Earnings	Nov 12 BMO	Avg Volume	24.17K	Price	3.04
SMA20	6.23%	SMA50	4.78%	SMA200	-17.99%	Trades		Volume	3,608	Change	-0.49%

Apr-14-25 07:00AM	COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer (GlobeNewswire)
Apr-09-25 05:00PM	COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) +15.10%
Apr-01-25 07:25PM	COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order (GlobeNewswire)
Mar-21-25 07:07AM	Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? (InsiderMonkey) -6.71%
Mar-19-25 07:33PM	COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents (Newsfile) +30.63% -21.15%
07:55AM	Loading…
Mar-13-25 07:55AM	COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product (GlobeNewswire) +15.61%
Dec-23-24 07:45AM	COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization (GlobeNewswire)
Nov-12-24 07:30AM	COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs (GlobeNewswire) -10.18%
Oct-08-24 07:30AM	COSCIENS Biopharma Announces Change to Board of Directors (GlobeNewswire)
Oct-01-24 05:30PM	COSCIENS Biopharma Announces Appointment of Pierre Labbe as Director (GlobeNewswire)
05:30PM	COSCIENS Biopharma Announces Appointment of Pierre Labb as Director (GlobeNewswire)
Sep-23-24 07:30AM	COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs (GlobeNewswire) -5.58%
Aug-27-24 07:30AM	COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency (GlobeNewswire) -32.42%
Aug-13-24 08:05AM	COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)

COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. It operates through the Active Ingredient and Biopharmaceutical segments. The Active Ingredient segment is involved in the development of proprietary extraction technologies. The Biopharmaceutical segment includes commercializing and developing pharmaceutical therapeutics and diagnostic tests. The company was founded on September 12, 1990 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CSCI

COSCIENS Biopharma Inc

Upgrade your FINVIZ experience